Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOXIRI + QL1706 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FOLFOXIRI + QL1706 + bevacizumab is an investigational combination chemo-immunotherapy regimen being evaluated for the first-line treatment of metastatic colorectal cancer (mCRC). This intensive regimen combines the FOLFOXIRI chemotherapy backbone (irinotecan, oxaliplatin, leucovorin, and 5-fluorouracil) with the anti-angiogenic monoclonal antibody bevacizumab and the novel bifunctional antibody QL1706. QL1706, developed by Qilu Pharmaceutical using its MabPair technology, is a single bifunctional antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The combination is designed to maximize anti-tumor activity by integrating cytotoxic chemotherapy, vascular normalization through VEGF inhibition, and dual immune checkpoint blockade. It is currently being studied in a Phase II trial led by Fujian Cancer Hospital specifically for patients with RAS/BRAF wild-type, left-sided metastatic colorectal cancer.
- Other names
- FOLFOXIRI + iparomlimab/tuvonralimab + bevacizumabFOLFOXIRI + QL1706 + Avastin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on FOLFOXIRI + QL1706 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOXIRI + QL1706 + bevacizumab.